It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Spontaneous cancers in companion dogs are robust models of human disease. Tracking tumor-specific immune responses in these models requires reagents to perform species-specific single cell T cell receptor sequencing (scTCRseq). scTCRseq and integration with scRNA data have not been demonstrated on companion dogs with cancer. Here, five healthy dogs, two dogs with T cell lymphoma and four dogs with melanoma are selected to demonstrate applicability of scTCRseq in a cancer immunotherapy setting. Single-cell suspensions of PBMCs or lymph node aspirates are profiled using scRNA and dog-specific scTCRseq primers. In total, 77,809 V(D)J-expressing cells are detected, with an average of 3498 (348 - 5,971) unique clonotypes identified per sample. In total, 29/34, 40/40, 22/22 and 9/9 known functional TRAV, TRAJ, TRBV and TRBJ gene segments are observed respectively. Pseudogene or otherwise defective gene segments are also detected supporting re-annotation of several as functional. Healthy dogs exhibit highly diverse repertoires, T cell lymphomas exhibit clonal repertoires, and vaccine-treated melanoma dogs are dominated by a small number of highly abundant clonotypes. scRNA libraries define large clusters of V(D)J-expressing CD8+ and CD4 + T cells. Dominant clonotypes observed in melanoma PBMCs are predominantly CD8 + T cells, with activated phenotypes, suggesting possible anti-tumor T cell populations.
A single cell TCRseq method for dogs that robustly detects TCR expression suggests reannotation of some non-functional VJ genes between diverse between diverse repertoires of healthy dogs and expanded repertoires in malignancies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Skidmore, Zachary L. 1 ; Rindt, Hans 2 ; Chu, Shirley 3 ; Fisk, Bryan 1 ; Foltz, Jennifer A. 4 ; Fronick, Catrina 5 ; Fulton, Robert 5 ; Zhou, Mingyi 6 ; Bivens, Nathan J. 6
; Reinero, Carol N. 2
; Fehniger, Todd A. 7 ; Griffith, Malachi 8
; Bryan, Jeffrey N. 2
; Griffith, Obi L. 8
1 Washington University School of Medicine, Division of Oncology, Department of Medicine, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, McDonnell Genome Institute, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
2 University of Missouri, Department of Veterinary Medicine and Surgery, Columbia, USA (GRID:grid.134936.a) (ISNI:0000 0001 2162 3504)
3 Washington University School of Medicine, Division of Oncology, Department of Medicine, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); University of Missouri, Department of Veterinary Medicine and Surgery, Columbia, USA (GRID:grid.134936.a) (ISNI:0000 0001 2162 3504)
4 Washington University School of Medicine, Division of Oncology, Department of Medicine, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
5 Washington University School of Medicine, McDonnell Genome Institute, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
6 University of Missouri, Genomics Technology Core, Columbia, USA (GRID:grid.134936.a) (ISNI:0000 0001 2162 3504)
7 Washington University School of Medicine, Division of Oncology, Department of Medicine, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Siteman Cancer Center, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
8 Washington University School of Medicine, Division of Oncology, Department of Medicine, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, McDonnell Genome Institute, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Siteman Cancer Center, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Department of Genetics, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)




